Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
April 03 2019 - 7:00AM
Summit Therapeutics plc (‘Summit’ or the
’Company’)
Summit’s Pipeline Expands with Series of New Mechanism
Antibiotics Targeting Enterobacteriaceae
- Data to be Presented in Oral Session at ECCMID
2019
Oxford, UK, and Cambridge, MA, US, 3
April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM), a leader in new mechanism antibiotic innovation, today
announces the expansion of its pipeline with a series of new
mechanism antibiotics, DDS-04, which targets Enterobacteriaceae.
Key data from this series will be presented in an oral session at
the 29th European Congress of Clinical Microbiology &
Infectious Diseases (‘ECCMID’), taking place 13-16 April 2019 in
Amsterdam.
“The DDS-04 series provides us with a major
opportunity to improve patient outcomes across several body sites
where Enterobacteriaceae cause infection,” said Dr David
Roblin, President of R&D of Summit. “We look forward
to developing the programme to show compelling clinical and
economic data that offer significant advantages over standard of
care for the patients in need.”
Summit’s DDS-04 series of new mechanism
antibiotic compounds acts specifically on Enterobacteriaceae via
LolCDE, an unexploited bacterial target. It is the first project to
emerge from the Company’s ESKAPE pathogen programme.
Enterobacteriaceae are a family of Gram-negative bacteria, which
include the critical threats Klebsiella pneumoniae and Escherichia
coli. These bacteria are responsible for a large number of severe
and often deadly infections of the bloodstream, lungs and urinary
tract. The DDS-04 series has shown activity across a global panel
of K. pneumoniae and E. coli strains, including strains resistant
to current standard of care treatments.
Details of the presentation are as follows:
Date: 14 April
2019Time: 1:42pm CESTSession:
Novel antimicrobial agents and discovery
strategiesLocation: Hall MTitle:
Novel Small-Molecule Inhibitors of Bacterial Lipoprotein Transport
with Potent Antimicrobial Activity against
EnterobacteriaceaeAuthors: E. Breidenstein, O.
Abdulle, T. Avis, C. Charrier, C. Ciardullo, C. Coward, T. Duffy,
N. Khan, C. Mason, P. Meo and D. Powell
About
EnterobacteriaceaeEnterobacteriaceae are a family of
Gram-negative bacteria responsible for a large number of severe and
often deadly infections of the bloodstream, lungs and urinary
tract. Increasing resistance of Enterobacteriaceae has rendered
many marketed antibiotics ineffective against these bacteria. Two
of the most alarming antibiotic resistance trends are
extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae
(CRE). ESBL is an enzyme that allows bacteria to become resistant
to a wide variety of penicillin and cephalosporin antibiotics.
ESBL-producing Enterobacteriaceae account for an estimated 26,000
infections annually in the US with 1,700 deaths, according to the
US Centers for Drug Control and Prevention (‘CDC’). CRE are
resistant to nearly all existing antibiotics, including carbapenems
which are considered the antibiotics of last resort. CRE account
for an estimated 9,000 infections per year in the US and 600
deaths, according to the CDC.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for infections caused by C. difficile, N. gonorrhoeae
and ESKAPE pathogens. We are using our proprietary Discuva Platform
to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK
office) |
Tel: |
44 (0)1235 443 951 |
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP
(Nominated Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom
Salvesen, Corporate Broking |
|
|
|
|
|
Bryan Garnier & Co Limited
(Joint Broker) |
Tel: |
+44 (0)20 7332 2500 |
Phil Walker / Dominic
Wilson |
|
|
MSL Group (US) |
Tel: |
+1 781 684 6557 |
Jon Siegal |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic
Communications (UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson
/ |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialisation of the Company’s product candidates, the
sufficiency of the Company’s cash resources, the timing of
initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals and other statements containing the words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, expectations for regulatory approvals, laws and
regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission, including the Company’s Annual Report on Form
20-F for the fiscal year ended 31 January 2018. Accordingly,
readers should not place undue reliance on forward-looking
statements or information. In addition, any forward-looking
statements included in this press release represent the Company’s
views only as of the date of this release and should not be relied
upon as representing the Company’s views as of any subsequent date.
The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024